Wemple writes, “Reuters says it hustled to set the record straight: ‘The original Reuters story misstated that ivermectin was ‘effective’ against Omicron in Phase III clinical trials, which are conducted in humans. We corrected this to clarify it had an ‘antiviral effect’ against Omicron and it was shown in joint nonclinical research. After being made aware of the error, we corrected our story immediately.’
“The Erik Wemple Blog asked Reuters about the newsworthiness of the story in its corrected incarnation. ‘We misinterpreted the Kowa announcement and corrected our story promptly to accurately reflect what the company said with the appropriate context,’ responded a Reuters spokesperson.
“We don’t doubt Reuters’s diligence in correcting itself; we doubt only how effective it’ll be. The mistaken report, after all, landed in a country where poison control centers last year were beset by an increase in ivermectin overdose calls — the byproduct of one strain of covid hype/misinformation.”
Read more here.
The Indianapolis Business Journal is looking for our next news editor, a role that focuses…
Axios has chosen Ben Berkowitz to be its next managing editor of business and markets.…
Business Insider editor in chief Jamie Heller sent out the following on Monday: I'm thrilled…
Rest of World editor in chief Anup Kaphle sent out the following on Monday: We are excited…
The Financial Times has hired Veena Venugopal as its India newsletter editor. She has been working at…
Benjamin Parkin has been named Middle East and Africa news editor at the Financial Times, based…